Loading
Appili Therapeutics Inc. Stock: price and insider trades · Canada
Insider Decl.
95
Thresholds
n/a
Buy Volume
€691,359
57 ops. · all time
Sell Volume
€324,715
21 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
CA$0.01
Analyst consensus
Income statement
RevenueCA$244.2k
EBITDA-CA$2.4M-987% margin
Net income-CA$4.2M-1736.7% margin
Valuation
Beta0.14
Balance sheet & cash
Total debtCA$12.9M
Free Cash Flow-CA$1.3M
Profitability & ownership
ROA-255.7%
% insiders0.1%
% institutions10.8%
Last declaration on 6 July 2026
Declarations95 total
100,000 sharesOptionsTSXSEDI:4746594
100,000 sharesOptionsTSXSEDI:4745557
75,000 sharesOptionsTSXSEDI:4745547
100,000 sharesOptionsTSXSEDI:4745516
100,000 sharesOptionsTSXSEDI:4745495
100,000 sharesOptionsTSXSEDI:4745421
Common Shares Class A Common SharesTSXSEDI:4135320
75,000 shares@ CA$0.04100.0% of flowCommon Shares Class A Common SharesTSXSEDI:4135321
Canonical exit: 6 Aug 2023 (T+90)
237,200 shares@ CA$0.1515Common Shares Class A Common SharesTSXSEDI:3838227
500 shares@ CA$0.001338.3% of flowCommon Shares Class A Common SharesTSXSEDI:3775805
Canonical exit: 6 Oct 2021 (T+90)
1,000 shares@ CA$0.64Common Shares Class A Common SharesTSXSEDI:3770525
Canonical exit: 28 Sept 2021 (T+90)
36,500 shares@ CA$0.7137Common Shares Class A Common SharesTSXSEDI:3767275
Canonical exit: 19 Sept 2021 (T+90)
35,000 shares@ CA$0.7569Common Shares Class A Common SharesTSXSEDI:3764494
Canonical exit: 13 Sept 2021 (T+90)
39,500 shares@ CA$0.8486Common Shares Class A Common SharesTSXSEDI:3749342
Canonical exit: 17 Aug 2021 (T+90)
100,000 shares@ CA$0.88Common Shares Class A Common SharesTSXSEDI:3749339
Canonical exit: 16 Aug 2021 (T+90)
500 shares@ CA$0.002261.7% of flowCommon Shares Class A Common SharesTSXSEDI:3698177
6,500 shares@ CA$1.0072Common Shares Class A Common SharesTSXSEDI:3698179
Canonical exit: 2 Jun 2021 (T+90)
4,700 shares@ CA$1.0502Common Shares Class A Common SharesTSXSEDI:3698178
Canonical exit: 1 Jun 2021 (T+90)
46,900 shares@ CA$1.2557Common Shares Class A Common SharesTSXSEDI:3682713
75,300 shares@ CA$1.353Common Shares Class A Common SharesTSXSEDI:3682710
83,700 shares@ CA$1.329Common Shares Class A Common SharesTSXSEDI:3682708
14,100 shares@ CA$0.9985Common Shares Class A Common SharesTSXSEDI:3670365
Canonical exit: 27 Apr 2021 (T+90)
9,200 shares@ CA$1.0917Common Shares Class A Common SharesTSXSEDI:3670363
Canonical exit: 26 Apr 2021 (T+90)
1,200 shares@ CA$1.1267Common Shares Class A Common SharesTSXSEDI:3667267
Canonical exit: 20 Apr 2021 (T+90)
27,100 shares@ CA$1.1158Common Shares Class A Common SharesTSXSEDI:3663881
Canonical exit: 15 Apr 2021 (T+90)
25 of 95 declarations
About Appili Therapeutics Inc.
A single holder of more than 10% drives the record of Appili Therapeutics Inc.: The K2 Principal Fund L.P. signs 50 of the 64 filings published between June 18, 2019 and July 6, 2026, of which 36 purchases and 12 sales. In all, the record shows 37 purchases and 12 sales, so purchases are 76% of market trades by count, but only 6 purchases and 2 sales carry a usable amount, so no overall value comes out of them.
Donald Cilla, a director, has 3 filings of which one purchase, Brian Matthew Bloom, a director, and Kevin Sullivan, a senior officer, 2 each, with no purchase or sale, and Prakash Gowd, a director, one. The record also holds 6 option exercises and 9 filings of another kind.
Read moreShow less
Activity is concentrated in 2020 (31 filings) and 2021 (19), against 6 in 2019, 2 in 2023 and 6 in 2026, and none in the other years. The Toronto company, classified under health care, is valued at CAD 661,830 and insiders hold 0.1% of it. The 6 filings of the last twelve months include no purchase or sale. The median publication delay is 3 days.
